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FMRP is an RNA-binding protein that is known to localize in the cytoplasm and in the nucleus. Here, we
have identified an interaction of FMRP with a specific set of C/D box snoRNAs in the nucleus. C/D box
snoRNAs guide 2’O methylations of ribosomal RNA (rRNA) on defined sites, and this modification
regulates rRNA folding and assembly of ribosomes. 2’Omethylation of rRNA is partial on several sites
in human embryonic stem cells, which results in ribosomes with differential methylation patterns.
FMRP-snoRNA interaction affects rRNA methylation on several of these sites, and in the absence of
FMRP, differential methylation pattern of rRNA is significantly altered. We found that FMRP recog-
nizes ribosomes carrying specific methylation patterns on rRNA and the recognition of methylation
pattern by FMRP may potentially determine the translation status of its target mRNAs. Thus, FMRP
integrates its function in the nucleus and in the cytoplasm.
INTRODUCTION
Fragile X mental retardation protein (FMRP) is an RNA-binding protein, loss of which leads to fragile X syn-
drome (Santoro et al., 2012). FMRP is recognized as a translation modulator, and its role in metabotropic
glutamate receptor (mGluR) signaling is extensively studied. Dysregulated synaptic translation in the
absence of FMRP is thought to be responsible for majority of the phenotypes in fragile X syndrome (Bassell
and Warren, 2008; Muddashetty et al., 2007, 2011; Richter et al., 2015). FMRP is also shown to have an
important role in neuronal development particularly during neuronal differentiation. The absence of
FMRP is reported to affect the maintenance of pluripotency, cell fate choice and rate of progression to
the neuronal lineages both in animal and human stem cell models (Li and Zhao, 2014; Luo et al., 2010; Telias
et al., 2013). Thus, FMRP-mediated regulation of translation is likely to be more global than confined to the
synapse. However, the mechanism of FMRP-mediated translation regulation beyond the synapse is not
understood.
FMRP is present in the cytosol as well as in the nucleus and localizes to the distal compartments in neurons.
A significant amount of FMRP has been reported to be present in the nuclear and nucleolar compartments
in neurons and other cell types (Eberhart et al., 1996; Feng et al., 1997b; Fridell et al., 1996; Kim et al., 2009;
Taha et al., 2014). However, the function of FMRP in nucleus still remains unexplained. Since it has both
nuclear localization and nuclear export signals, FMRP is proposed to be involved in the shuttling of its
target mRNAs between the nucleus and cytosol (Kim et al., 2009). A mutation in the nuclear localization
signal was also reported to cause fragile X-like syndrome (Collins et al., 2010). In addition, there is an
intriguing possibility that FMRPmight interact with a distinct class of RNA in the nuclear/nucleolar compart-
ments and play a crucial role in global translation regulation.
Translational regulation by FMRP has been reported through its direct interaction with the 60S subunit of the
ribosome (Chen et al., 2014; Khandjian et al., 1996). A mutation affecting FMRP’s interaction with ribosomes
leads to a severe form of mental retardation (Feng et al., 1997a; Myrick et al., 2014), whereas its interaction
with mRNAs is not affected by this mutation. According to these evidences, we postulate that FMRP has an
important function in the nucleus, which could modulate its function in the cytoplasm. Here, we report an
interesting interaction of FMRP with a subset of small nucleolar RNAs (snoRNAs) in the nuclear compartmentiScience 9, 399–411, November 30, 2018 ª 2018 The Author(s).
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of human embryonic stem cells (hESCs) and neuronal precursor cells (hNPCs) derived from these hESCs.
FMRP’s interaction with snoRNAs contributes to differential methylation of rRNA, generating ribosome het-
erogeneity. The absence of FMRP results in an alteration of this methylation pattern. On the other hand,
FMRP also recognizes specific methylation patterns on rRNA and hence marks a subset of ribosomes. Our
results identify a nuclear function of FMRP and imply that it can integrate translation regulation between
the nucleus and cytoplasm.
RESULTS AND DISCUSSION
FMRP Interacts with a Selected Subset of snoRNAs
To investigate the small RNAs that interact with FMRP during neuronal development, we used human H9
hESCs and H9 neuronal precursor cells (hNPCs) as our model system. H9 hESCs were characterized for
pluripotency by immunocytochemistry with the marker OCT4 (Figure 1A), and similarly, hNPCs were
characterized for the expression of Nestin (Figure 1B). In H9 hESCs, we show that FMRP interacts with
AGO2, a primary component of the miRNA induced silencing complex (miRISC) (Figure 1C) indicating
its interaction with microRNA machinery. In our initial observations, other than microRNA, we found
another class of RNA (80–100nt) predominantly present in the FMRP immunoprecipitates. To identify
this unknown class of small RNAs, we performed an FMRP immunoprecipitation (IP) with H9 hESCs and
hNPCs followed by small RNA library preparation from both the microRNA band (30–50 nt) and
the higher-molecular-weight band (80–100 nt). An AGO2 IP was used as a positive control to profile the
microRNAs (Figure 1D). The libraries were separated on a 6% polyacrylamide gel and showed a prominent
band in AGO2 IP at a size of 140 bp representing the population of microRNAs (Figure 1D).
Surprisingly, the prominent band in FMRP IP was identified at a much higher size (around 200 bp) (Figures
1D and S1A). We isolated the bands corresponding to both 140 and 200 bp from the FMRP IP samples and
sequenced them separately (Figure 1E). We have included a mouse IgG control in this experiment, and
since there was insignificant RNA precipitated with this (Figures 1C and S1B) compared to FMRP IP, it
was not further considered for preparation of cDNA library. The band corresponding to 140 bp in FMRP
IP majorly contained microRNAs (data not shown) similar to that in the AGO2 IP. Interestingly, the major
component of the 200-bp band (corresponding to 80–100 nt RNAs) from the library was C/D box snoRNAs
(Figures 1F and 1G). In contrast, AGO2 IP from hESCs and hNPCs showed negligible amount of snoRNA
(Figures S1D and S1E) compared with the input (Figure S1C). The library profile of the 200-bp band (corre-
sponding to snoRNA) derived from FMRP IP was similar in both hESCs and hNPCs as depicted by the
principal-component analysis plot (Figure 1H). Top snoRNAs associated with FMRP in hESCs are listed
in Table S1, and all these snoRNAs are predicted to target and methylate specific sites on 18S or 28S ribo-
somal RNA.
We validated the interaction of FMRP with snoRNA by performing qPCR for the snoRNAs that were
highly enriched in the FMRP IP from H9 hESC lysate (Figure 2A). Our qPCR primers were designed
such that an entire snoRNA was amplified from the FMRP IP, suggesting that FMRP interacts with
the mature snoRNA (as determined by the sequencing data) rather than the products derived from
their further processing (Brameier et al., 2011; Taft et al., 2009). All the selected snoRNA candidates
showed a significant enrichment in FMRP IP (pellet/input ratio), compared with the corresponding
IgG control (Figure 2A). In contrast, none of the snoRNAs were enriched in the AGO2 pellet (Fig-
ure S2B). The small fraction of snoRNA (5%) found in the AGO2 pellet (Figure S1D) could be small
RNA derived from further snoRNA processing. The mature full-length snoRNA we tested for were absent
in this sample. To confirm that FMRP’s interaction with these snoRNAs is specific, we performed IP with an
antibody against a different epitope of FMRP (Figure S2A). We further validated FMRP’s interaction with
target snoRNAs in a different human ESC line (Shef4) (Figure S2C) and in HeLa cells (Figure 2B) as well.
Our results indicate that the interaction of FMRP with snoRNAs is a common feature among all the cell
types we tested.
FMRP Directly Interacts with C/D Box snoRNA
Our next objective was to test whether FMRP directly interacts with C/D box snoRNAs. To study this, we
performed an electrophoretic mobility shift assay with purified full-length human FMRP (Figure S2D). For
this we chose SNORD80, one of the top snoRNA candidates which we found to be associated with
FMRP in our high-throughput analysis (Tables S1 and S2). SNORD80 was radiolabeled with g-P-ATP and
was incubated with increasing concentrations of FMRP (from 100 nM to 14.6 mM). We observed a shift in400 iScience 9, 399–411, November 30, 2018
Figure 1. FMRP Interacts with Selected Set of C/D Box snoRNAs in Human ESCs and NPCs
(A) Characterization of H9 hESCs with pluripotency marker OCT4 and nuclear marker DAPI (scale bar, 50 mm).
(B) Characterization of H9 hNPCs with differentiation marker Nestin and nuclear marker DAPI (scale bar, 50 mm).
(C) Immunoblot for FMRP and AGO2 from H9 hESC lysate after FMRP and IgG immunoprecipitation.
(D) Polyacrylamide gels showing mobility of cDNA libraries prepared from RNA extracted after immunoprecipitation with
FMRP and AGO2 from H9 hESC and hNPC lysate.
(E) Schematic showing the experimental workflow to identify FMRP-associated small RNAs.
(F) Pie chart showing the distribution of different classes of small RNAs from the sequence obtained from the 200-bp band
of the library from H9 hESCs, n = 3.
(G) Pie chart showing the distribution of different classes of small RNAs from the sequence obtained from the 200-bp
band of the library from H9 hNPCs, n = 3.
(H) Principal component analysis (PCA) chart indicating clustering of snoRNA libraries in H9 hESCs and H9 hNPCs, hESC
FMRP IP n = 3, hNPC FMRP IP n = 3, hESC Input n = 1, and hESC AGO2 IP n = 2.SNORD80 mobility even with an FMRP concentration of 500 nM (Figure 2C), which was further enhanced in
a concentration-dependent manner, indicating a direct interaction of SNORD80 with FMRP. The shift in
SNORD80 mobility was completely reversed by incubation with molar excess of unlabeled SNORD80 (Fig-
ure 2C-lane 8). This competition was seen only with unlabeled SNORD80 and not with nonspecific bacterial
RNA (lane 9 and 10) along with yeast tRNA, which was used in all other lanes thus confirming the specific
interaction of SNORD80 with FMRP. Although we demonstrate the direct interaction of FMRP with one of
the candidate snoRNAs, we cannot rule out the possibility that FMRP’s interaction with C/D box snoRNAs
may also be mediated through other snoRNP components or other nuclear FMRP interacting proteins such
as NUFIP1 (Bardoni et al., 2003).iScience 9, 399–411, November 30, 2018 401
Figure 2. Validation of FMRP Interaction with C/D Box snoRNA
(A) Validation of FMRP-interacting snoRNA in human H9 hESCs by qPCR with representative immunoblot for FMRP IP
(n = 6, unpaired Student’s t test, mean G SEM).
(B) Validation of FMRP-interacting snoRNA in HeLa cells by qPCR with representative immunoblot for FMRP IP (n = 4,
unpaired Student’s t test, mean G SEM). Also refer Tables S1 and S2.
(C) Electrophoretic mobility shift assay showing shift in mobility of radiolabeled SNORD80 by increasing concentration of
His-FMRP. Lane 8 shows a complete abolishment of shift with molar excess of unlabeled (cold) SNORD80 RNA. Lanes 9
and 10 indicated no change in the mobility of His-FMRP with radiolabeled non-specific bacterial RNA. Samples in lanes 9
and 10 were run on a separate gel.Among the two major classes of snoRNAs involved in rRNA modifications (C/D box snoRNAs that mediate
2-O’methylation and H/ACA box snoRNAs that mediate pseudo-uridylation) (Falaleeva et al., 2017; Henras
et al., 2015), we detected only C/D box snoRNAs in the FMRP pellet. We did see a weak higher-molecular-
weight band in the cDNA library prepared from the FMRP pellet (Figure S1A); however, we did not find any
H/ACA box snoRNA or precursor snoRNA when we sequenced this band (data not shown). Thus, FMRP
appears to interact only with C/D box snoRNA, although we cannot completely rule out an interaction
with H/ACA box snoRNA in the FMRP pellet. Since H/ACA box snoRNAs possess complex secondary struc-
tures, there is a possible bias against them in the cDNA library preparation.
The specific interaction with C/D box snoRNAs indicates that FMRP seems to have an important role in
rRNA methylation. These C/D box snoRNAs primarily guide the 2’O methylation on selected ribose sugars
on rRNA, which is important for the folding of the rRNA and the assembly of ribosomal proteins (Falaleeva
et al., 2017; Sharma and Lafontaine, 2015). Some snoRNAs are also reported to generate smaller RNAs,
includingmicroRNAs (Brameier et al., 2011), found in the cytoplasm. Here, we show that FMRP’s interaction
with snoRNAs is only confined to the nuclear fraction (Figure 3G). Also, it interacts with full-length snoRNAs
and not the processed small RNA products of snoRNAs.
A group of snoRNAs without specific targets on rRNA (called orphan snoRNAs) are also known to have a
role in mRNA splicing (Kishore and Stamm, 2006). All top snoRNA candidates precipitated with FMRP402 iScience 9, 399–411, November 30, 2018
Figure 3. Interaction of Nuclear FMRP with C/D Box snoRNA
(A) Immunostaining of H9 hESCs (blue-DAPI, red-FMRP, and scale bar, 5 mm) followed by segmented images showing
nuclear distribution of FMRP (scale bar, 1 mm).
(B) Quantification of nuclear FMRP in H9 hESCs, n = 29 cells.
(C) Immunoblots showing the distribution of FMRP in H9 hESC nuclear and cytoplasmic fractions, Lamin as nuclear marker
and Tubulin as cytoplasmic marker.
(D) Immunoblots for FMRP and Fibrillarin followed by FMRP or Fibrillarin immunoprecipitation from nuclear fractions of
H9 hESCs.
(E) Immunoblots showing the distribution of FMRP in HeLa nuclear and cytoplasmic fractions with Lamin as nuclear marker
and Tubulin as cytoplasmic marker.
(F) Immunoblots for FMRP and Fibrillarin followed by FMRP or Fibrillarin immunoprecipitation from nuclear fractions of
HeLa cells.
(G) qPCR for selected snoRNAs after immunoprecipitation with FMRP from nuclear and cytoplasmic lysates of H9 hESCs.
Values are the ratio of pellet/input of the cytoplasmic fraction normalized to the pellet/input ratio of the nuclear fraction
(n = 3, unpaired Student’s t test, mean G SEM).
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have predicted target sites on rRNA, and we did not find any orphan snoRNA enriched in the pellet
(Table S1). These results clearly suggest that the interaction of FMRP with snoRNA is likely to have a role
in rRNA methylation.
Interaction with snoRNA Is a Function of Nuclear FMRP
Although FMRP is often studied as a cytoplasmic protein, it has a nuclear localization signal, and its local-
ization to the nucleus is reported by several studies (Kim et al., 2009; Taha et al., 2014). Here we show a local-
ization of FMRP in the nucleus of H9 hESCs (Figure 3A) by FMRP immunostaining overlaid with DAPI, a
nuclear marker. Similarly, we observed FMRP’s localization in the nucleus of Neuro2A (Figure S3A), HeLa
(Figure S3B), rat cortical neurons (Figure S3C), and rat astrocytes (Figure S3D) confirming that FMRP is pre-
sent both in the nucleus and cytoplasm of the all the cell types that we studied. We quantified the percent-
age of FMRP in the nucleus based on DAPI staining (Figure 3B) and found that nearly 50% of FMRP localized
in the nucleus of hESCs. Since the nucleus of ESCs is relatively large, we expect the ratio of nuclear to cyto-
plasmic FMRP to be lower in other cell types (Figures S3A–S3D). We also confirmed that FMRP’s localization
in the nucleus is specific through immunostaining with an antibody raised against a different epitope of
FMRP (Figure S3E). To establish the compartment-specific localization of FMRP, we used nuclear and cyto-
plasmic fractions from H9 hESCs (Bensaddek et al., 2016) and probed for the presence of FMRP. The purity
of the fractionation was validated by LaminB1 and a-Tubulin as nuclear and cytoplasmic markers respec-
tively (Figure 3C). FMRP was found to be present in both nuclear and cytoplasmic fractions (Figure 3C).
The sequence between the C and D0 box (or C0 and D) is complementary to a specific region on rRNA, and
this complementarity determines the site to be methylated (Cavaille et al., 1996). RNA-binding proteins
forming the snoRNP complex are recruited to these sites by C/D box snoRNAs, and 2’O-methylation is
carried out by a nucleolar-specific methyltransferase, Fibrillarin (Shubina et al., 2016). Since FMRP has a
putative nucleolar localization signal and has been shown to localize to the nucleolus (Taha et al., 2014),
we tested whether it interacts with Fibrillarin. For this, we probed for the presence of Fibrillarin in FMRP
immunoprecipitates from the nuclear fraction of H9 hESCs. We did not see a co-precipitation of Fibrillarin
with FMRP (Figure 3D). Similarly, we did not see FMRP in the Fibrillarin immunoprecipitate (Figure 3D). We
tested for this interaction in nuclear extracts of HeLa (Figures 3E and 3F) and Neuro2A (Figure S3F) and did
not find FMRP co-precipitating with Fibrillarin in any of these experiments. These results strongly suggest
that FMRP and Fibrillarin are likely to be present in separate RNPs, although both interact with snoRNA.
Finally, to confirm that the interaction of FMRP with snoRNA is in the nucleus, we performed an FMRP IP
from H9 hESC nuclear and cytoplasmic fractions followed by qPCR for selected target snoRNAs. We found
that these snoRNAs are significantly enriched in immunoprecipitates from nuclear fractions compared with
cytoplasmic fractions (Figures 3G and S3G). Thus, FMRP-snoRNA interaction is primarily in the nuclear
compartment and seems to be distinct from Fibrillarin-containing snoRNPs. FMRP may sequester specific
snoRNAs and control their availability to rRNA methylation machinery and regulate the extent of methyl-
ation. Similarly, other RNA-binding proteins might be involved in regulating rRNA methylation through
their interaction with snoRNAs cumulatively leading to the differential rRNA methylation.
Differential 2’O-Methylation of rRNA in Human ESCs
So far 106 methylation sites have been identified on human rRNA (Falaleeva et al., 2017; Incarnato et al.,
2017; Machnicka et al., 2013). Recently it was reported that the differential methylation of selected sites
on rRNA can give rise to ribosome heterogeneity as demonstrated in HeLa cells (Krogh et al., 2016). To
establish the differential rRNA methylation in human ESCs, we estimated the extent of rRNA methylation
of known sites in Shef4 hESCs using the recently developed high-throughput RiboMeth sequencing
method (Marchand et al., 2017). In this method, ribosomal RNA extracted from hESCs was subjected to par-
tial alkaline hydrolysis, followed by library preparation and sequencing (See Transparent Methods section).
The sequenced data were analyzed to estimate the extent of methylation using a previously described
(Krogh et al., 2016) bioinformatics pipeline (Figure S4A). In our assay we detected 97 sites in Shef4 hESC
rRNA. A majority of the sites are completely methylated (methylation index close to 1); however, 9 sites
on 18S rRNA (Figure 4A) and 15 sites on 28S rRNA were only partially methylated (methylation index signif-
icantly lower than 1) (Figure 4B) as reflected in Table S3. The extent of methylation on these sites varied
from a methylation index of 0.6 to 0.9 (Figures 4A and 4B), which denotes that these sites are methylated
in 60%–90% of the ribosomes, whereas they are unmethylated in the remaining 10%–40% of the ribosomes.
The heterogeneity of rRNAmethylation we observed in hESCs is distinct from that of HeLa cells as reported
previously (Krogh et al., 2016).404 iScience 9, 399–411, November 30, 2018
Figure 4. Ribosomal RNA 2’O-Methylation Pattern in Shef4 and Shef4 FMR1 KO hESCs
(A) Methylation index of the sites on 18S rRNA in Shef4 hESCs. The x axis represents the respective methylation position
on 18S rRNA, and y axis represents the fraction methylated, n = 3.
(B) Methylation index of the sites on 28S rRNA in Shef4 hESCs. The x axis represents the respective methylation position
on 28S rRNA, and y axis represents the fraction methylated, n = 3.
(C) Immunoblots showing absence of FMRP in Shef4 FMR1 KO hESCs with Tubulin as the control.
(D) Change in levels of top snoRNA candidates in Shef4WT and Shef4 FMR1 KO hESCs by qPCR (n = 5, unpaired Student’s
t test, mean G SEM).
(E) Sites in 18S and 28S rRNA that show 5% or more difference in the methylation index between Shef4 hESCs and Shef4
FMR1 KO hESCs (n = 3, mean G SEM).Absence of FMRP Alters the rRNA 2’O-Methylation Pattern in Human ESCs
We observe that FMRP interacts with a specific subset of C/D box snoRNAs (Table S1), and we wanted to
test if the absence of FMRP will have any effect on the level of its target snoRNAs at steady state. For this weiScience 9, 399–411, November 30, 2018 405
generated Shef4 FMR1 knockout (KO) hESCs using the CRISPR-Cas9 system (Figures 4C and S4B–S4E) and
performed a qPCR for these candidate snoRNAs. Surprisingly, at steady state, we did not see any signifi-
cant change in the level of FMRP target snoRNAs in FMR1 KO cells (Figure 4D). Since most of the snoRNAs
we found associated with FMRP were C/D box snoRNA, we studied the impact of this interaction (FMRP-
snoRNA) by looking at 2’Omethylation in Shef4 wild-type (WT) and Shef4 FMR1 KO hESCs (Figures 4E, S4F,
and S4G). We performed a high-throughput RiboMethSeq fromWT and FMR1 KO hESCs as described pre-
viously. On comparing the methylation profile between WT and KO cells, we found that the sites that were
fully methylated in WT (methylation index 1) were unaffected in the absence of FMRP (Figures S4F and
S4G). Interestingly, many sites in 18S and 28S rRNA that were partially methylated in WT hESCs were signif-
icantly altered in the absence of FMRP (Figure 4E and Table S3).
We independently validated the change in methylation of rRNA in the absence of FMRP for selected sites
(Figure 5A) by a qPCR-based method called RTL-P (Dong et al., 2012) (Figure S5A). RTL-P has been previ-
ously used to identify the differential methylation of rRNA (Dong et al., 2012), and we have further tested
the validity of this assay (Figures S5A–S5G). This method involves the amplification of PCR products under
high and low dNTP concentrations for each primer set. There are two forward primers, one positioned up-
stream (P1) and other downstream (P2) of the methylation site. Amplification was done using a reverse
primer (P3) downstream of the methylation site (Figure S5A). For RTL-P we have considered the smaller
PCR product (from P2 and P3) as our control in both high and low dNTP conditions (since it is unaffected
by methylation). Then we have quantified the larger PCR product (from P1 and P3) at similar conditions and
normalized it to its respective smaller PCR product (Figures S5B and S5C). Example of RTL-P analysis for a
given site has been provided in Transparent Methods. We have validated two selected sites 401 (complete
methylation) and 4917 (partial methylation) through RTL-P. The PCR products were run on a gel, and the
bands corresponding to the upstream product (*) were selectively cut out and cloned into a bacterial vector
(Figures S5B and S5C) for Sanger sequencing (Figures S5F and S5G). Furthermore, we validated site 4917 in
WT and in FMR1 knockdown HeLa cells. We observe that the intensity of the amplicon generated for the
knockdown samples under low dNTPs is lesser compared to that of the WT (Figures S5D and S5E). Here,
we clearly show that under low and high dNTP conditions, we observe the PCR reaction stopping down-
stream and upstream of the methylation site as expected (Figures S5F and S5G).
We chose sites for RTL-P validation based on our high-throughput sequencing as well as sites that were
targeted by our top snoRNA candidates. Our RTL-P results were similar to that of the RiboMethSeq. Sites
429, 2416 and 4917 are significantly hypo-methylated in FMR1 KO compared to WT. Site 4307 was signif-
icantly hyper-methylated in FMR1 KO, whereas the methylation on site 401 was unaltered (Figure 5A).
Apart from these, we also show that site 3680 (targeted by FMRP associated SNORD88A) is significantly
hyper-methylated in the FMR1 KO, although there was no difference in RiboMethSeq (Figure 5A). These
results confirm that absence of FMRP has a significant impact on the methylation status of specific rRNA
sites.
Heterogeneity among ribosomes is an emerging concept and provides a new dimension for translation
regulation (Lafontaine, 2015; Shi et al., 2017). Modifications on rRNA, including snoRNA-guided methyl-
ation, are proposed to play an important role in contributing to heterogeneity (Falaleeva et al., 2017). How-
ever, themechanism by which differential modification of rRNA occurs is not explored. Our work for the first
time defines an interaction of an RNA-binding protein, FMRP, with a specific subset of C/D box snoRNAs.
This interaction may have an influence in regulating rRNA methylation in humans. In the absence of FMRP,
methylation was altered for 12 (5 on 18S rRNA and 7 on 28S rRNA) of 28 differentially methylated sites as
identified by RiboMethSeq. Interestingly, sites that show an alteredmethylation in the absence of FMRP are
the ones that also show partial methylation in the control (WT) hESCs (methylation index less than 1). This
implies that FMRP has an important role in differential methylation of rRNA and has a significant contribu-
tion in generating ribosome heterogeneity.Acute Knockdown or Overexpression of FMRP Alters rRNA 2’O-Methylation Pattern
To verify that the change in 2’O-methylation observed is FMRP specific, we acutely knocked down FMRP
(48 hr with siRNA, Figures 5B, 5C, and S5H) and overexpressed FLAG-FMRP (24 hr Figures 5H and S5I) in
HeLa cells. Following FMRP knockdown or overexpression, we estimated the methylation of rRNA on
selected sites through RTL-P (Figures 5D–5F and 5H–5J). On acute knockdown of FMRP, we observed
hypo-methylation on the sites 2416, 4456, and 4917 (Figure 5E). The hypo-methylation of these sites on406 iScience 9, 399–411, November 30, 2018
Figure 5. Validation of Change in rRNA 2’O-Methylation Pattern by FMRP
(A) RTL-P for selected sites on 18S and 28S rRNA to show differences in methylation in Shef4 WT and Shef4 FMR1 KO hESC lysate (n = 3, unpaired Student’s
t test, mean G SEM).
(B) Schematic for reverse transcription followed by PCR (RTL-P) on FMR1 knockdown or FMRP overexpression in HeLa cells.
(C) Representative immunoblots for FMRP showing its knockdown in HeLa cells with Tubulin as a control.
(D–F) RTL-P for selected sites showing the change in 2’O-methylation on FMR1 knockdown in HeLa cells (n = 3, unpaired Student’s t test, mean G SEM).
(G) Representative immunoblots for FMRP showing overexpression of FLAG-FMRP in HeLa cells with Tubulin as a control.
(H–J) RTL-P for selected sites showing the change in 2’O-methylation on overexpression of FLAG-FMRP in HeLa cells (n = 3, unpaired Student’s t test,
mean G SEM).FMRP knockdown is the same as we have identified in FMR1 KO hESCs both by high-throughput
RiboMethSeq (Figure 4E) and RTL-P-based analysis from the same cells (Figure 5A). Sites 2788 and 4307,
which showed hyper-methylation in FMR1 KO hESCs, also showed hyper-methylation on acute knockdown
of FMRP in HeLa cells (Figure 5F). These results confirm that the change in methylation in FMR1 KO hESCs
could be reproduced by acute knockdown of FMRP. In contrast, the effect of acute overexpression of FMRP
was more complex. One of the sites (176), which showed hyper-methylation in FMR1 KO hESCs (Figure 4E),
showed a hypo-methylation on FMRP overexpression (Figure 5I) in HeLa cells. Similarly, a site (4917) that
showed hypo-methylation in FMR1 KO hESCs showed hyper-methylation on FMRP overexpression (Fig-
ure 5J), clearly indicating that the presence or absence of FMRP is the direct cause of change in methyl-
ation. Site 401, which was unaffected in FMR1 KO hESCs, remained unchanged (with respect to its methyl-
ation) on FMRP knockdown or overexpression in HeLa cells (Figures 5D and 5H). Although acuteiScience 9, 399–411, November 30, 2018 407
Figure 6. Recognition of rRNA 2’O-Methylation by FMRP
(A) Immunoblots showing the presence of ribosomal protein RPLP0 in FMRP immunoprecipitate from H9 hESC nuclear
fractions.
(B) Relative methylation index of H9 hESC rRNA from FMRP IP normalized to input by RTL-P (n = 3–4, unpaired Student’s
t test, mean G SEM).
(C) Model illustrating the role of FMRP in regulating translation through differential rRNA methylation.knockdown of FMRP reproduces the results of FMR1 KO, overexpression of FMRP has inconsistent effects.
Overexpression may have limited effects owing to saturating concentration of endogenous FMRP.
Overall, our results indicate that absence of FMRP can lead to either hypo- or hyper-methylation on distinct
sites. FMRP may sequester specific snoRNAs and control their availability to rRNA methylation machinery
and regulate the extent of 2’O-methylation. However, the role of FMRP in controlling status of methylation
is unclear; identifying the other components (both protein and RNA) involved is needed to address this
issue.
FMRP Recognizes Differential 2’O-Methylation Pattern
We have demonstrated that FMRP interacts with a subset of snoRNAs in the nuclear compartment. In the
absence of FMRP, rRNA 2’O-methylation is significantly altered and this affects ribosome heterogeneity.
We also show that FMRP interacts with ribosomal proteins (Figure 6A) as also previously reported (Chen
et al., 2014) (Simsek et al., 2017). Based on these results we wanted to investigate if FMRP can recognize
the 2’O-methylation pattern on ribosomes. For this we performed FMRP immunoprecipitation and408 iScience 9, 399–411, November 30, 2018
isolated rRNA, which was pulled down with FMRP. We quantified the extent of 2’O-methylation of
selected sites on rRNA by RTL-P and compared it with the extent of methylation to ribosomes in the
input (Figure 6B). We chose the sites whose methylation is altered in the absence of FMRP. Among
them, three sites showed a significant difference in the FMRP pellet compared to the input. Site 429
(18S rRNA) showed a trend of hyper-methylation in the FMRP pellet, whereas sites 2416 and 4917 (28S
rRNA) were hypo-methylated compared to the input. Site 401 remained unchanged (Figure 6B). There
was no difference in the methylation pattern for these sites in the control IP with IgG (Figure S6B). These
results indicate that FMRP binds to the ribosome preferentially when site 429 is methylated in 18S rRNA
and 2416 and 4917 are unmethylated in 28S rRNA. Although we show that FMRP interacts with ribosomal
proteins in the nuclear fraction (Figure 6A), currently we do not know whether this recognition of rRNA
methylation pattern by FMRP happens during the assembly of ribosomes or later. Our initial experiments
indicate that FMRP shows a better interaction with rRNA when it is from cell lysate rather than with pu-
rified rRNA (Figure S6A).
An interesting possibility is that the heterogeneity influenced by FMRP (in the form of differential rRNA
methylation) is recognized by FMRP itself and thus recruits a subset of ribosomes for the translation of
its own target mRNAs (Figure 6C-model). Our results indicate that FMRP recognizes differential 2’O-
methylation pattern on selected sites of rRNA. Interestingly, there are many G-quartet structures (an
RNA motif recognized by FMRP) that lie in close proximity to these rRNA methylation sites, which
might be regulated by FMRP (Figure S6C). An altered methylation on these sites could influence the
G-quartet structures, which interact with FMRP. We propose this to be the mechanism by which
FMRP recognizes ribosomes based on differential rRNA methylation on specific sites (Figure 6C-
model).Limitations of the Study
This study focused on the interaction of FMRP with C/D box snoRNA in the nucleus. Our data suggests that
the interaction of FMRP with specific C/D Box snoRNAmight affect 2’O-methylation on rRNA. At the mech-
anistic level, our data can correlate only the levels of FMRP and the consequent change in methylation of
specific sites. We show that FMRP and Fibrillarin (rRNA-specific methyltransferase) are in separate com-
plexes, and we do not know the exact molecular mechanism involving the FMRP-snoRNA complex and
how it regulates changes in rRNA post-transcriptional modifications in a cell.
We know from our data that FMRP can bind to the ribosome, especially through the RNA component. We
propose a putative model describing how the rRNAmethylation pattern can be recognized by FMRP based
on a bio-informatics prediction, but we currently do not have any experimental evidence to prove that. Our
data demonstrates the link between FMRP’s interaction with a subset of C/D box snoRNAs and rRNA
methylation. Although we have evidence regarding the recognition of specific 2’O-methylation patterns
by RNA binding proteins (RBPs) like FMRP, we are yet to understand the correlation between the role of
FMRP in rRNAmethylation, FMRP’s recognition of specific methylation patterns, and translation regulation
of specific subset of mRNAs, which is beyond the scope of our manuscript.METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods, six figures, and three tables and can be found
with this article online at https://doi.org/10.1016/j.isci.2018.11.007.ACKNOWLEDGMENTS
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Figure S1- FMRP interacts with selected set of C/D box snoRNAs in human ESCs and 
NPCs. (Related to Figure 1) 
 
 
A-Polyacrylamide gels showing mobility of cDNA libraries prepared from RNA extracted after 
immunoprecipitation with FMRP and AGO2 from H9 hESC and hNPC lysate. B- 
Electropherogram for RNA extracted from FMRP IP (top panel) and IgG IP (bottom panel). C-Pie 
chart representing the distribution of various kinds of RNAs in hESC input library, n=1. D- Pie 
chart representing distribution of various kind of RNAs in hESC AGO2 library, n=2. E- Pie chart 
representing distribution of various kind of RNAs in hNPC AGO2 library, n=1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure S2- Validation of FMRP interaction with C/D box snoRNA. (Related to Figure 2) 
 
A- Validation of top snoRNA candidates in H9 hESCs with antibody raised against a different 
epitope of FMRP for immunoprecipitation (Sigma, F4055), n=2, mean ± SD. B- Validation of 
snoRNA candidates in H9 hESCs after FMRP and AGO2 immunoprecipitation. n=2, mean ± SD   
C- Validation of snoRNA candidates in Shef4 hESCs with FMRP immunoprecipitation (n=3, 
mean ± SEM, Unpaired Student’s t-test). D- Coomassie staining of purified His-FMRP protein 
with varying concentrations of Imidazole containing elution buffer. Maximum elution was 
visualized at 500 nM Imidazole. 
 
 
 
 
 
 
Figure S3- Interaction of Nuclear FMRP with C/D box snoRNA. (Related to Figure 3)
 
Nuclear FMRP (Red) staining in Neuro2A (A), HeLa (B), rat cortical neurons (C) and rat astrocytes 
(D) with DAPI (Blue) staining as a nuclear marker. Scale bar 5 µm.  E-Nuclear FMRP (red) staining 
in rat cortical neurons with DAPI as a nuclear marker. Antibody used is raised against different 
epitope of FMRP (Scale bar 10 µm). F-Immunoprecipitation of FMRP and Fibrillarin in cytoplasmic 
and nuclear fractions of Neuro2A with IgG used as a negative control. G- qPCR for selected 
snoRNAs after immunoprecipitation with FMRP from nuclear and cytoplasmic lysates of H9 
hESCs.  Values are the ratio of nuclear pellet / Input normalized to the pellet/input ratio of the 
cytoplasmic fraction (n=3, Unpaired Student’s t-test, mean ± SEM). 
Figure S4- Ribosomal RNA Methylation pattern in Shef4 WT and Shef4 FMR1 KO hESCs 
(Related to Figure 4) 
 
 A- Pipeline for analysis of RiboMeth sequencing data indicating details of tools and parameters 
used for analysis. B-The strategy for producing FMR1 KO hESCs with the position of the guide 
RNA for CRISPR/Cas9 mediated deletion. C- PCR screening of the clones. The positive clones 
have PCR amplicon of around 450 bps and the negative clones have the PCR amplicon of about 
100 bp. D- FMRP western blot for screening the positive clones for absence of FMRP expression 
at protein level. The positive clones are marked by *. E- Representative Sanger sequence of the 
Shef4 FMR1 KO hESC clone G3. F-Comparison of methylated fractions between Shef4 WT hESC 
and Shef4 FMR1 KO hESCs along 18S rRNA. X-axis represents the respective methylation 
position on 18S rRNA and Y-axis represent fraction methylated, scale from 0 (min) to 1 (max), 
n=3. G- Comparison of methylated fractions between Shef4 WT hESC and Shef4 FMR1 KO cells 
along 28S rRNA. X-axis represent the respective Methylation position on 28S rRNA and Y-axis 
represent fraction methylated, scale from 0 (min) to 1 (max), n=3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure S5- Validation of change in rRNA methylation pattern by FMRP    (Related to 
Figure 5) 
 
 
A- Schematic of primer design for RTL-P of a given position along rRNA. B and C-Agarose gel 
images representing 2’O methylation for sites 4917 and 401 along Shef4 hESC rRNA. Images 
show PCR products under low dNTP conditions with primers P1-P3 and P2-P3. * Indicates the 
band that is Sanger sequenced. D and E- Agarose gel images representing 2’O methylation for 
site 4917. PCR products were generated under low dNTP and high dNTP conditions using P1 
and P3 primers. F and G-Ligated PCR products of methylation positions 4917 and 401 were 
transformed and colony selected before Sanger sequencing. Reads indicate the exact position of 
2’O methylation using the downstream reverse primer (P2). H- Quantification of FMRP knock 
down in HeLa cells (n=4, mean ± SEM, Unpaired Student's t-test). I- Schematic depicting the 
Flag-Halo-GFP-tagged WT human FMRP overexpression construct.  
  
Figure S6- Recognition of rRNA methylation by FMRP. (Related to Figure 6) 
 
A-In vitro binding assay of pure human His-FMRP protein and total cell lysate / purified 
RNA to check the direct interaction of FMRP and 28S rRNA quantified by qPCR, Primers 
used were P2 and P3 corresponding to site 401. n=3. B- Change in methylation index 
between IgG IP samples and input. Plot represents values normalized to input (n=3-4, 
Unpaired Student’s t-test, mean ± SEM). C- In silico depiction (Swiss-PDB Viewer) of 28S 
rRNA G-Quartet in close proximity to FMRP recognition site 2416 and 4917. 
  
Supplementary Tables 
Table S1-Enrichment of top snoRNA candidates associated with FMRP in H9 hESCs. 
(Related to Figure 1) 
snoRNA HGNC nomenclature Site targeted on rRNA 
U95 SNORD95 small nucleolar RNA, C/D box 95 28S rRNA A2802 and C2811 
U81 SNORD81 small nucleolar RNA, C/D box 81 28S rRNA A401 
U33 SNORD33 small nucleolar RNA, C/D box 33 18S rRNA U1326 
U41 SNORD41 small nucleolar RNA, C/D box 41 28S rRNA U4276. 
U80 SNORD80 small nucleolar RNA, C/D box 80 28S rRNA A1521 and G1612 
U32A SNORD32A small nucleolar RNA, C/D box 32A 18S rRNA G1328 and 28S rRNA 
A1511 
U56 SNORD56 small nucleolar RNA, C/D box 56 18S rRNA C517 
U105B SNORD105B small nucleolar RNA, C/D box 
105B 
18S rRNA U799 
U28 SNORD28 small nucleolar RNA, C/D box 28 18S rRNA C1391 
U26 SNORD26 small nucleolar RNA, C/D box 26 28S rRNA A389 
U42A SNORD42A small nucleolar RNA, C/D box 42A 18S rRNA U116 
HBII-99 SNORD12 small nucleolar RNA, C/D box 12 28S rRNA G3878 
U59B SNORD59B small nucleolar RNA, C/D box 59B 18S rRNA A1031 
U106 SNORD12C small nucleolar RNA, C/D box 12C 18S rRNA G1536 and U1602 
HBII-202 SNORD68 small nucleolar RNA, C/D box 68 18S rRNA U428 and 28S rRNA 
A2388 
U55 SNORD55 small nucleolar RNA, C/D box 55 28S rRNA C2791 
HBII-180C SNORD88C small nucleolar RNA, C/D box 88C 28S rRNA C3680 
U102 SNORD102 small nucleolar RNA, C/D box 102 28S rRNA G4020 
U49A SNORD49A small nucleolar RNA, C/D box 49A 28S rRNA C4426 
HBII-420 SNORD99 small nucleolar RNA, C/D box 99 28S rRNA A2774 
HBII-55 SNORD110 small nucleolar RNA, C/D box 110 18S rRNA U1288 
U104 SNORD104 small nucleolar RNA, C/D box 104 28S rRNA C1327 
HBII-210 SNORD69 small nucleolar RNA, C/D box 69 28S rRNA G4464 
HBII-99B SNORD12B small nucleolar RNA, C/D box 12B 28S rRNA G3878 
U44 SNORD44 small nucleolar RNA, C/D box 44 18S rRNA A166 
U42B SNORD42B small nucleolar RNA, C/D box 42B 18S rRNA U116 
U25 SNORD25 small nucleolar RNA, C/D box 25 18S rRNA G1490 
U57 SNORD57 small nucleolar RNA, C/D box 57 18S rRNA A99 
U37 SNORD37 small nucleolar RNA, C/D box 37 28S rRNA A3697 
mgh28S-2409 SNORD5 small nucleolar RNA, C/D box 5 28S rRNA C2409 
SNORD119 SNORD119 small nucleolar RNA, C/D box 119 28S rRNA A4560 
U18A SNORD18A small nucleolar RNA, C/D box 18A 28S rRNA A1313 
U61 SNORD61 small nucleolar RNA, C/D box 61 18S rRNA U1442 
U35A SNORD35A small nucleolar RNA, C/D box 35A 28S rRNA C4506 
U30 SNORD30 small nucleolar RNA, C/D box 30 28S rRNA A3804 
U24 SNORD24 small nucleolar RNA, C/D box 24 28S rRNA C2338 and C2352 
U58B SNORD58B small nucleolar RNA, C/D box 58B 28S rRNA G4198 
SNORD126 SNORD126 small nucleolar RNA, C/D box 126 Unknown target 
U75 SNORD75 small nucleolar RNA, C/D box 75 28S rRNA C4032 
U43 SNORD43 small nucleolar RNA, C/D box 43 18S rRNA C1703 
 
 
Table S2-Top snoRNA candidates showing more than 2 fold enrichment in the FMRP 
pulldown when compared to the input. (Related to Figure 1) 
Top snoRNA FMRP IP Input 
U95 102760 2437 
U81 154548 4531 
U33 53353 2386 
U41 25018 1313 
U80 106248 5953 
U32A 48269 3992 
U56 10909 1053 
U105B 179656 18161 
U28 11161 1321 
U26 45306 5622 
U42A 326677 43105 
HBII-99 412639 64471 
Values indicate the un-normalized raw reads of respective snoRNA in the Input (n=1) and the 
mean un-normalized raw reads for the FMRP IP (n=3).  
 
 
 
 
 
Table S3-Sites showing at least 5% change in methylation on rRNA.(Related to Figure 4) 
rRNA Methylated 
position 
Methylation index 
WT KO 
18S A175 0.695 0.765 
 C429 0.789 0.767 
 A669 0.895 0.941 
 G868 0.919 0.833 
 C1249 0.860 0.657 
 T1392 0.961 0.914 
 A1448 0.417 0.274 
28S A2366 0.924 0.879 
 G2416 0.874 0.775 
 T2788 0.949 0.869 
 A2825 0.817 0.858 
 T3745 0.769 0.812 
 G3868 0.963 0.904 
 A3945 0.962 0.902 
 A4307 0.803 0.897 
 C4456 0.911 0.847 
 C4917 0.753 0.609 
 
  
Transparent Methods 
Ethics Statement 
All the work was done with due approval from the Institutional Animal Ethics committee (IAEC) 
and the institutional biosafety committee (IBSC), InStem, Bangalore, India.  
Generation of Shef4 FMR1 KO cells 
 Shef4 FMR1 KO hESCs were generated using CRISPR-Cas9 technology (Figure S4C-G). The 
gRNA sequences used to delete 450 bp region which includes the 5’UTR and exon 1 for 
generating the knockout are as follows-  
FMR1 gRNA Fw: 5’-cagcgttgatcacgtgacg-3' 
FMR1 gRNA Rev: 5’-ggcgcggtgctcgggaaga-3 
 Clones were screened through PCR where the positive clones have PCR amplicon of around 
450bps and the negative clones have the PCR amplicon of about 100bp. Western blots for the 
screened positive clones showed absence of FMRP expression at protein level. The positive 
clones are marked by *. FMR1 KO hESC clone G3 which was used for experiments was Sanger 
sequenced further 
Cell line and Embryonic Stem Cell culture 
H9 hESCs were cultured on Matrigel (BD Biosciences, 3545277) coated plates containing 
mTeSR1 medium (StemCell Technologies, 5850) at 37°C in a 5% CO2 environment. Cells were 
further passaged with an enzyme cocktail containing 1 mg/ml of Collagenase type IV (Invitrogen), 
20%  KOSR (Gibco), 0.25% Trypsin and 1 mM CaCl2 dissolved in 1X PBS without CaCl2 or 
MgCl2  pH 7.2. For immunostaining experiments, H9 hESC colonies were plated on Matrigel 
coated glass coverslips and cultured as mentioned above. 
H9 hESCs were further differentiated to Neural Precursor Cells (hNPCs) by inducing them with 
medium containing DMEM/ F12/ Advanced neurobasal medium (1:1), 1% N2, 1% B27 without 
Retinoic acid, 1% L-glut,0.1% Pen/Strep and the inhibitors SB431542 (SMAD inhibitor 10µM) and 
LDN193189 (Noggin analog 0.1 µM) for 14 days. The hNPCs were further expanded in medium 
containing DMEM/F12 / Advanced neurobasal medium(1:1), 1% N2, 1% B27 without retinoic acid, 
1% L-glut,0.1% Pen/Strep , FGF2 (10 ng/ml) and EGF ( 10 ng/ml) (Shi et al., 2012). 
Shef4 WT and Shef4 FMR1 KO hESCs were maintained on Matrigel coated plates containing 
Essential 8™ Medium (ThermoFisher Scientific (A15169-01) and passaged with a 1:1 solution of 
2 mg/ml Collagenase type IV (Gibco 17104-019) and 1 mg/ml Dispase (Gibco 17105-041). 
Collagenase and Dispase stock solutions were prepared in Advanced DMEM-F12 (Gibco 12634-
010).  
HeLa and Neuro2A cells were maintained in DMEM containing 10% FBS and 1% Penicillin-
Streptomycin at 37°C in a 5% CO2 environment passaged using 0.05% trypsin-EDTA solution. 
Primary neuronal cultures were prepared from E18 rat pups (Sprague Dawley) according to an 
established lab protocol (Kaech and Banker, 2006). Neurons were dissociated and cultured on 
Poly-l-lysine coated coverslips in defined Neurobasal Medium supplemented with B-27 and 
Glutamax. Neurons were cultured for 5 days at 37°C in a 5% CO2 incubator (low density 2500 
cells per sq.cm). Astroglia were obtained from the same animal as that of the neurons and grown 
in MEM supplemented with 10% FBS and 1X Glutamax for 2 weeks. 
 
Immunostaining 
Cells were fixed with 4% PFA before staining. The cells were permeabilized with TBS-50T (0.3 
%) [50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 0.3% TritonX-100] followed by treatment with Tris-
Glycine solution (0.5 M Tris and 0.2 M Glycine). The cells were blocked with buffer containing 2 
% BSA and 4 % FBS. Cells were incubated with primary antibody overnight at 4°C and Alexa fluor 
coupled anti-mouse 488 and anti-rabbit 555 secondary antibodies at room temperature for 2 
hours. The cells were finally incubated with DAPI for 5mins before being mounted with Mowiol® 
4-88 mounting medium. For quantification of FMRP in hESCs, Images were acquired on Olympus 
FLUOVIEW 3000 confocal laser scanning microscope (Olympus Corporation) with 60X PlanApo 
N, NA- 1.42, oil immersion objective. For maximum resolution both in the XY direction and Z 
direction, Images were acquired using optical zooming of 2.5x to satisfy the sampling theorem of 
Nyquist, pinhole was kept at 1 Airy unit and stacks in the Z direction were acquired with a step 
size of 0.3μm. Imaging conditions were kept constant across different data sets, across 
experiments. 
Image Analysis: Image analysis was done Bitplane IMARIS 9.0 (Bitplane, oxford Instrument 
Company) software. For quantifying intensity within the nucleus, DAPI Channel was used to make 
volumetric nuclear mask and FMRP channel was used to make volumetric mask the entire cell. 
Local background correction was done using a radius of 5-10 μm while making the masks. 
Subsequently, integrated intensity was calculated for FMRP channel within both nuclear mask 
and whole cell mask and was plotted as a ratio of nuclear and cytoplasmic intensity for multiple 
cells from 3 independent experiments. The distribution was then checked for normality.   
 
Immunoprecipitation 
Cells were lysed in a 1 % NP40 containing lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 
mM MgCl2 with protease and RNase inhibitors) and spun at 18000 rcf (12500 rpm) for 20 minutes 
at 4°C. Precleared supernatant was used for immunoprecipitation with Protein G Dynabeads. 5 
μg of anti-FMRP/ AGO2/ Fibrillarin/Flag antibody was coupled to the Protein G Dynabeads. 
Similar amount of normal mouse/rabbit IgG antibody was used as a control. 
 
Cellular fractionation 
H9 hESCs and HeLa cells were trypsinised (0.25 % trypsin) and centrifuged down at 1000 rpm 
for 5 minutes at 25°C. The pellet was lysed with a 0.1% NP40 containing lysis buffer (20 mM Tris-
Cl pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM DTT) with gentle trituration. 1/3rd of the volume 
was spun down at 10,000 rpm and the supernatant was used as the cytoplasmic input. The 
remaining 2/3rd of the lysate was gently layered over a 1 M sucrose cushion and spun at 2800 g 
for 20 minutes at 4°C. The final nuclear pellet was suspended in a 1 % NP40 containing lysis 
buffer and used for further experiments. 
 
Small-RNA sequencing 
H9 hESCs and hNPCs were lysed with a 1 % NP40 containing buffer and centrifuged at 18000 
rpm for 20 minutes at 4°C. The supernatant obtained was used for immunoprecipitation with 
FMRP and AGO2 antibodies at room temperature for 1hour. Whole cell lysates were used to 
generate input libraries which were also sequenced. Antibody bound RNA was extracted from the 
respective pellets using the Trizol method of extraction. Isolated RNA was used for library 
preparation using TruSeq small RNA library kit from Illumina (Cat- RS-930-1013). The prepared 
libraries were resolved on a 6 % PAGE gel with TBE buffer. Bands corresponding to 150 bp and 
200 bp were excised out and separately sequenced by HiSeq 1000.  
 
Analysis of small-RNA sequencing 
The raw reads from each of this library were uniformly processed. The first step involved removal 
of adapter sequence (5’ TGGAATTCTCGGGTGCCAAGG 3’) from the reads using cutadapt 
(Martin, 2011) with the parameters –q 30 (quality score) and –minum-length 36 (minimum length 
of the read after trimming). The trimmed and processed reads were then further analyzed to filter 
out the reads corresponding to rRNA. The gencodeV19 was used to derive the sequences of 
rRNA from hg19 version of the genome and the reads that mapped to these rRNA sequences 
were removed. The remaining reads were then aligned to the genome using the bowtie 
(Langmead et al., 2009) with parameters ‘-q --best -m 1 -k 1 --chunkmbs 200’ to ensure that 
unique reads are mapped to the genome. The total number of reads in the library, trimmed, filtered 
and aligned are tabulated in Supplementary Table 2. The ‘Homo_sapiens.GRCh37.75.gtf’ 
annotation was used to derive the counts for individual features using HTSeq (Anders et al., 
2015). The MDS plot for these 10 samples were derived using edgeR package in R (Robinson et 
al., 2010). The PCA plot measures the similarity of the samples and projects this measure on to 
two dimensions. A filter of at least 1 read per million in at least one of the ten samples was used 
for PCA analysis. In all the FMRP pull down libraries, on average 33% of the reads were 
associated with snoRNAs. The aligned bam files generated were converted to bed and the 
overlap analysis with the annotated snoRNAs in UCSC genome browser was performed using 
bedtools (Quinlan and Hall, 2010) to get the counts for each type of snoRNA. 
 
RiboMethSeq and analysis 
Total RNA from Shef4 WT and Shef4 FMR1 KO cells was extracted and 2 μg of RNA was used 
for library preparation. Further, RNA was hydrolysed with an alkaline Tris buffer, pH 10 at 95°C 
for 5 minutes. Hydrolysed RNA was precipitated by ethanol and run on a 12 % PAGE gel with 
TBE as running buffer. After separation, the band around 30-50 bp was excised out (Figure 1D 
and Figure S1A). The library was prepared according to the TruSeq small RNA library 
preparation protocol from Illumina and sequencing was done on Hiseq 3000 instrument. 
Preliminary trimming of adapter sequence was done using Cutadapt v1.8.3 (Martin, 2011) with 
the following parameters: adapter (Illumina Small RNA), average quality: 30, minimum length: 17 
bp, maximum length: 45 bp. Alignment to the reference rRNA sequence was done by Bowtie 
v1.1.2 (Langmead et al., 2009) with parameters: -v=2 (end-to-end mode) and k-1 (one good 
alignment per read). Computed the number of 5' read-ends and 3' read-ends that are mapped to 
each positions of reference rRNA using Bedtools v2.25.0. The 5' and 3' read-ends counts were 
shifted to obtain the actual methylated positions based on the alignment to methylated nucleotide 
in the reference sequence. Ultimately, two datasets from 5' and 3' read-ends counts were 
combined for calculation of RiboMeth-seq scores. Optimal cut-off values for detection of 
methylations were determined using Matthews’s correlation coefficient using ROCR package 
(Sing et al., 2005).  
 
Data Availability 
Sequencing data for both Shef4 hESC RiboMethseq and H9 hESC snoRNA have been deposited 
at NCBI Genbank under the following identifiers. 
RiboMethseq- https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA407420 
snoRNA-   https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA407706 
 
 Constructs 
Human FMRP gene was amplified (1900bp) from Addgene plasmid (cat no #48690) and sub 
cloned into EGFP-C1 vector named as EGFP-FMRP. The gene encoding HALO tag was inserted 
before EGFP sequence of EGFP-FMRP construct using Overlap extension PCR to give Flag-
HALO-EGFP-FMRP (Flag-FMRP) which was used for over expression experiments. Full length 
human FMRP gene was again cloned into pET28a+ bacterial expression vector along with a 6X 
His tag which was used for protein expression and purification later. 
 
Overexpression or knockdown experiments  
Flag-FMRP construct was transfected to HeLa cells using Lipofectamine 2000transfection 
reagents as per manufacturer instruction (Invitrogen, 11668019) and incubated for 24 hours. The 
over-expression of these constructs was confirmed by the presence of GFP fluorescence using 
fluorescence microscope (IX 73, Olympus).Knockdown of FMRP was performed using FMR1-
siRNA with Lipofectamine 2000 transfection reagent and incubated for 48 hours. Knockdown was 
confirmed by western blotting and comparing against α-Tubulin. 
 
FMRP expression and purification 
 Human FMRP with 6X His tag was cloned in a pET28a vector and transformed into Rosetta DE3 
competent cells. Cells were incubated overnight in the presence of kanamycin (50ug/ml).  The 
expression of FMRP ISO1 was induced in 4lt of culture with isopropyl β-D-1-
thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM for 16 hours at 18ᵒC. The final 
bacterial pellet was lysed in buffer containing 20 mM HEPES pH 8.0, 500 mM NaCl, 10 mM MgCl2, 
10 mM β-mercaptoethanol, 10% glycerol. Clarified bacterial lysate was added on to an 
equilibrated Ni-NTA column (Life Technologies, R90115). Purified His-FMRP was eluted in 
fractions using buffer containing a gradient of 100 mM to 500 mM imidazole. Protein stocks were 
dialysed to remove the imidazole, concentrated and flash frozen with 10% glycerol. 
 
RNA labelling and EMSA 
 SNORD80 was in vitro transcribed using recombinant T7 RNA polymerase purified in the lab.  
This was treated with Calf Intestinal alkaline Phosphatase (NEB M0290S) and 5’end labelled with 
γ-[32P] ATP. Nonspecific bacterial RNA was in vitro transcribed in a similar manner. Radiolabeled 
RNA (~10 fmol @ 20 CPS/µl) was incubated with increasing amounts of His-FMRP in buffer 
containing 25 mM Tris Ph8, 5 mM MgCl2, 10% glycerol 2 mM DTT and 150 mM NaCl in the 
presence of 2.5 ng/µl yeast tRNA and 10 U of RNAseOUT for 1 hour at RT. 10 M (280 pmoles) 
excess of unlabeled SNORD80 was used in a reaction to compete out the binding between 
radiolabeled SNORD80 and the maximum concentration of His-FMRP (14.6 µM). 7 µl of the 
reaction mixture were loaded in IX TBE / 5% native gel (5% acrylamide: bis (80:1). and run at 
100V for approximately 40 minutes in cold. The gel was dried and exposed overnight using 
Typhoon FLA 7000 Phosphorimager.  
 
Validation of RTL-P assay. 
PCR amplification of the RTLP products was performed using methylation specific forward and 
reverse primers. 2 µL of reaction products was run on 3% agarose gel and imaged using 
Amersham Imager 600. Specific bands were cut out from the gel and purified (QIAquick, 28704). 
Product was re-ligated into a vector (pCR2.1 -TOPO) using the TOPO TA cloning standard 
protocol. Positive (white) colonies were selected and propagated. Plasmids were isolated (Qiagen 
plasmid Miniprep isolation spin, 27104) and subjected to Sanger sequencing.   
 
In vitro RNA immunoprecipitation 
Shef4 FMR1 KO ESCs cells were lysed in a 1 % Triton-X 100 containing 1X EMSA buffer and 
spun at 18000 rcf for 20 minutes at 4°C to clear the lysate. Similarly hESC total RNA was extracted 
using Trizol LS. 5 μg of anti-FMRP antibody was coupled to Protein G Dynabeads at RT for 30 
min followed by equimolar concentrations of purified FMRP protein which was incubated for 30 
min at RT. For immunoprecipitation, equimolar concentration cell supernatant or RNA was 
incubated with the protein bound beads for 30 min at RTwith 1X EMSA buffer. RNA was eluted 
and rRNA quantified by qPCR. 
 
RTL-P (Reverse transcription at low-dNTP concentration followed by PCR)  
2 ng of sample RNA was used for cDNA preparation using reverse primers (10 μM) specific to 
methylation sites under high dNTP (10 mM) and low dNTP (1 nM) concentrations.  For real time 
PCR, we adopted a method from (Dong et al., 2012). We have used two forward primers for a 
methylation site; one up-stream (P1) and one down-stream (P2) from the methylation site, along 
with a common reverse primer (P3). Amplification with these sets of primers would yield one 
product over the methylation site which will be the longer product and other will be within the 
methylation site and would yield a small length product (Figure S5A). The extent of methylation 
at a given site was measured as an RTLP as mentioned below. 
RTLP score calculation  
Ct low- Ct High (Upstream primer) =X 
Ct low- Ct High (Downstream primer) =Y 
Ribometh score = 2^ (X-Y) 
The RiboMeth score is then normalized to corresponding control (WT vs KO, Input vs IP). 
Example of calculation of methylation index for a site 4917 on 28S by RTL-P 
                      P1                         P2                                 P3  
       rRNA  
  
 
Step 1: Ct values for each site with methylation specific upstream and downstream primer are 
done using high and low dNTP concentration.  
  P1-P3 P1-P3 P2-P3 P2-P3 
High dNTP 19.21 19.35 13.88 13.57 
Low dNTP 23.59 23.23 15.34 15.38 
NTC 34.23 32.08 31.97 36.94 
 
Step 2: Average of the Upstream and downstream Ct values 
  P1-P3 (x) P2-P3   (y) 
High dNTP 19.28 13.72 
Low dNTP 23.41 15.36 
NTC 32.08 31.97 
 
Step 3: Subtract the Upstream Ct value from the Downstream Ct value  
  y-x 
High dNTP 5.5576 
Low dNTP 8.05 
 
Step 4: Subtract the High dNTP values from Low dNTP value  
 Low-High 
WT 2.4934 
 
Step 5: 2^-(Low-High) the value from step 4  
 2^- (Low-High) 
Un-normalized 
Methylation Index 5.631 
 
Table above represents the value of absolute methylation index. Further, we can calculate 
relative methylation index based on considered normalization factor. 
WH -Wild type High 
WL -Wild type Low 
NTC – No template control 
 
 
 Statistical Analysis 
Statistical significance was calculated using Unpaired Student’s t-test for all biochemical and 
qPCR assays. For imaging quantifications, distribution of data points was assessed using 
Shapiro-Wilk’s test. For RiboMethseq, Matthew’s correlation coefficient was used to obtain values 
with an optimal cut-off to detect the 2’O- Methylation. All data was plotted as Mean ± SEM unless 
mentioned otherwise. Values with p<0.05 was considered statistically significant. 
 
